Dr. Ken Rosenfield, added, Vortex Medical has created game changing technology - facilitating en bloc removal of intravascular material during the performance of extracorporeal circulation. The Angiovac devices represent a new and innovative platform
(PRWEB) July 29, 2011
These distinguished physicians bring Vortex a wealth of clinical backgrounds, device development experience, market knowledge and hospital based operational insights that are very relevant to the growth of Vortex Medical. The scientific advisors include:
Kenneth Rosenfield, M.D., Section Head for Vascular Medicine and Intervention at the Massachusetts General Hospital in Boston. Dr. Rosenfield is Board Certified in Cardiovascular Disease, Internal Medicine, and Interventional Cardiology. He has been recognized as one of America’s Top Doctors by Castle Connelly for the past two consecutive years.
Willard M. Daggett, M.D., Professor of Surgery, emeritus, at Harvard Medical School and retired Massachusetts General Hospital cardiac surgeon. He is founder of the MGH Laboratory of Surgical Cardiovascular Physiologic Research.
Michael D. Dake, M.D., Professor of Cardiothoracic Surgery at Stanford School of Medicine. He serves as Medical Director of Catheterization and Angiography Laboratories and is Chief of Interventional Radiology.
Michael R. Jaff, D.O., FACP, FACC, FAHA, Associate Professor of Medicine at Harvard Medical School. He serves as Medical Director of Massachusetts General Hospital’s Vascular Center, Medical Director of Massachusetts General Hospital’s Vascular Diagnostic Laboratory, and Medical Director of Massachusetts General Hospital’s Vascular Ultrasound Core Laboratory
Christopher J. Kwolek, M.D., Director of the Vascular and Endovascular training program at Massachusetts General Hospital and Chief of Vascular Surgery at Newton Wellesley Hospital.
For Full Bios of each scientific advisory board member, please visit: http//http://www.angiovac.com/scientific-advisory-board
"We assembled a team of innovative thought leaders who recognize the potential of Vortex Medical to change the way that physicians view the catheter based treatment of venous thromboembolism," said Michael Glennon, chief executive officer and co-founder of Vortex Medical. "Their wealth of knowledge and skills will help drive innovative development of the next generation of Angiovac devices and clinical applications."
Dr. Ken Rosenfield, added, "Vortex Medical has created game changing technology - facilitating en bloc removal of intravascular material during the performance of extracorporeal circulation. The Angiovac devices represent a new and innovative platform that has the potential to positively impact the lives of our patients. The Vortex SAB is looking forward to a focused systematic approach to improving the technology for the benefit of generations of physician users and their patients."
Vortex' customer base includes interventional cardiologists and radiologists, vascular and endovascular surgeons, cardiac surgeons, perfusionists and the nurses and techs that support each specialty. Vortex Medical is developing patient centric endomechanical solutions to commonly occurring endovascular problems. Vortex Medical is developing our technology with a focus on project and process management, speed, capital efficiency and diligence. Vortex Medical is proud to be building and launching our platform technology in the USA!